Renaissance Capital logo

Valeritas Holdings Priced, Nasdaq: VLRX

Markets a disposable device that delivers insulin therapy for Type 2 diabetes.

Industry: Health Care

First Day Return: -28.8%

Industry: Health Care

We are a commercial-stage medical technology company focused on improving health and simplifying life for people with diabetes by developing and commercializing innovative technologies. We designed our first commercialized product, the V-Go Wearable Insulin Delivery Device, or V-Go, to help patients with Type 2 diabetes who require insulin to achieve and maintain their target blood glucose goals. V-Go is indicated for continuous subcutaneous infusion of insulin over 24 hours and on-demand bolus dosing in two-unit increments in adult patients requiring insulin. V-Go is a small, discreet and easy-to-use disposable insulin delivery device that a patient adheres to his or her skin. V-Go is not considered durable medical equipment because it is not intended for repeated use. Each V-Go device is designed to be worn for 24 hours, removed from the body and disposed. V-Go enables patients to closely mimic the body’s normal physiologic pattern of insulin delivery throughout the day and to manage their diabetes with insulin without the need to plan a daily routine around multiple daily injections.
more less
IPO Data
IPO File Date 02/06/2017
Offer Price $10.00
Price Range $9.00 - $11.00
Offer Shares (mm) 5.3
Deal Size ($mm) $53
Lock-Up Date IPO Pro Only
Street Research IPO Pro Only
IPO Data
IPO Date 03/22/2017
Offer Price IPO Intelligence Only
Price Range IPO Intelligence Only
Offer Shares (mm) IPO Intelligence Only
Deal Size ($mm) $53
Lock-Up Date IPO Intelligence Only
Street Research IPO Intelligence Only
Underwriters
IPO Intelligence Only
Company Data
Headquarters Bridgewater, NJ, United States
Founded 2006
Employees at IPO 82
Website www.valeritas.com

Valeritas Holdings (VLRX) Performance